Macroscale delivery systems for molecular and cellular payloads

Nature Materials

Volumn 12, Issue 11, 2013, Pages 1004-1017

  Kearney, Cathal J ^a,b   Mooney, David J ^a,b  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOACTIVE AGENTS; CARRIER MATERIAL; DELIVERY SYSTEMS; PRECISE CONTROL; SMALL MOLECULES; SPATIOTEMPORAL CONTROL; THERAPEUTIC TARGETS; TREATMENT SITES;

BIOMEDICAL EQUIPMENT; CELL ENGINEERING; DRUG DELIVERY; DRUG INTERACTIONS; TISSUE; TISSUE ENGINEERING;

DISEASE CONTROL;

BIOMATERIAL;

ANIMAL; CELLS; CHEMISTRY; DEVICES; DRUG DELIVERY SYSTEM; HUMAN; METABOLISM; PROCEDURES; EQUIPMENT; METHODOLOGY; REVIEW;

ANIMALS; BIOCOMPATIBLE MATERIALS; CELLS; DRUG DELIVERY SYSTEMS; EQUIPMENT AND SUPPLIES; HUMANS;

EID: 84886311125     PISSN: 14761122     EISSN: 14764660     Source Type: Journal    
DOI: 10.1038/nmat3758     Document Type: Review

References (165)

1. Dang, J. M. & Leong, K. W. Natural polymers for gene delivery and tissue engineering. Adv. Drug Deliv. Rev. 58, 487-499 (2006).
2. Folkman, J., Long, D. M. & Rosenbaum, R. Silicone rubber: A new diffusion property useful for general anesthesia. Science 154, 148-149 (1966).
3. Hoffman, A. S. The origins and evolution of 'controlled' drug delivery systems. J. Control. Release 132, 153-163 (2008).
4. Langer, R. & Folkman, J. Polymers for the sustained release of proteins and other macromolecules. Nature 263, 797-800 (1976).
5. Kanasty, R., Dorkin, R. J., Vegas, A. & Anderson, D. Delivery materials for siRNA therapeutics. Nature Mater. 12, 967-977 (2013).
6. Irvine, D. J., Swartz, M. A. & Szeto, G. L. Engineering synthetic vaccines using cues from natural immunity. Nature Mater. 12, 978-990 (2013).
7. Mura, S., Nicolas, J. & Couvreur, P. Stimuli-responsive nanocarriers for drug delivery. Nature Mater. 12, 991-1003 (2013).
8. Roseman, T. J. Release of steroids from a silicone polymer. J. Pharm. Sci. 61, 46-50 (1972).
9. Pitt, C. G., Gratzl, M. M., Jeffcoat, A. R., Zweidinger, R. & Schindler, A. Sustained drug delivery systems II: Factors affecting release rates from poly(?-caprolactone) and related biodegradable polyesters. J. Pharm. Sci. 68, 1534-1538 (1979).
10. Langer, R. Polymeric delivery systems for controlled drug release. Chem. Eng. Comm. 6, 1-48 (1980).
11. Augst, A., Kong, H. & Mooney, D. Alginate hydrogels as biomaterials. Macromol. Biosci. 6, 623-633 (2006).
12. Young, S., Wong, M., Tabata, Y. & Mikos, A. G. Gelatin as a delivery vehicle for the controlled release of bioactive molecules. J. Control. Release 109, 256-274 (2005).
13. Bhattarai, N., Gunn, J. & Zhang, M. Chitosan-based hydrogels for controlled, localized drug delivery. Adv. Drug Deliv. Rev. 62, 83-99 (2010).
14. Janmey, P. A., Winer, J. P. & Weisel, J. W. Fibrin gels and their clinical and bioengineering applications. J. R. Soc. Interface 6, 1-10 (2009).
15. Uhrich, K. E., Cannizzaro, S. M., Langer, R. S. & Shakesheff, K. M. Polymeric systems for controlled drug release. Chem. Rev. 99, 3181-3198 (1999).
16. Tanaka, H., Matsumura, M. & Veliky, I. A. Diffusion characteristics of substrates in Ca-alginate gel beads. Biotechnol. Bioeng. 26, 53-58 (1984).
17. Lin, C-C. & Metters, A. T. Hydrogels in controlled release formulations: network design and mathematical modeling. Adv. Drug Deliv. Rev. 58, 1379-1408 (2006).
18. Am Ende, M. T. & Peppas, N. A. Transport of ionizable drugs and proteins in crosslinked poly(acrylic acid) and poly(acrylic acid-co-2- hydroxyethyl methacrylate) hydrogels. I. Polymer characterization. J. Appl. Polym. Sci. 59, 673-685 (1996).
19. Am Ende, M. T. & Peppas, N. A. Transport of ionizable drugs and proteins in crosslinked poly(acrylic acid) and poly(acrylic acid-co-2- hydroxyethyl methacrylate) hydrogels. II. Diffusion and release studies. J. Control. Release 48, 47-56 (1997).
20. Silva, A. K. A., Richard, C., Bessodes, M., Scherman, D. & Merten, O-W. Growth factor delivery approaches in hydrogels. Biomacromolecules 10, 9-18 (2009).
21. Peppas, N. A., Bures, P., Leobandung, W. & Ichikawa, H. Hydrogels in pharmaceutical formulations. Eur. J. Pharm. Biopharm. 50, 27-46 (2000).
22. Peppas, N. A., Hilt, J. Z., Khademhosseini, A. & Langer, R. Hydrogels in biology and medicine: From molecular principles to bionanotechnology. Adv. Mater. 18, 1345-1360 (2006).
23. Lee, K., Silva, E. A. & Mooney, D. J. Growth factor delivery-based tissue engineering: General approaches and a review of recent developments. J. R. Soc. Interface 8, 153-170 (2011).
24. Gupta, P., Vermani, K. & Garg, S. Hydrogels: From controlled release to pH-responsive drug delivery. Drug Discov. Today 7, 569-579 (2002).
25. Hoare, T. R. & Kohane, D. S. Hydrogels in drug delivery: Progress and challenges. Polymer 49, 1993-2007 (2008).
26. Lu, S. & Anseth, K. S. Photopolymerization of multilaminated poly(HEMA) hydrogels for controlled release. J. Control. Release 57, 291-300 (1999).
27. Galaev, I. Y. & Mattiasson, B. 'Smart' polymers and what they could do in biotechnology and medicine. Trends Biotechnol. 17, 335-340 (1999).
28. Miyata, T., Asami, N. & Uragami, T. A reversibly antigen-responsive hydrogel. Nature 399, 766-769 (1999).
29. Zhang, J. & Peppas, N. A. Synthesis and characterization of pH- and temperature-sensitive poly(methacrylic acid)/poly(N-isopropylacrylamide) interpenetrating polymeric networks. Macromolecules 33, 102-107 (2000).
30. Wang, N. X. & von Recum, H. A. Affinity-based drug delivery. Macromol. Biosci. 11, 321-332 (2011).
31. Borselli, C. et al. Functional muscle regeneration with combined delivery of angiogenesis and myogenesis factors. Proc. Natl Acad. Sci. USA 107, 3287-3292 (2010).
32. Pike, D. B. et al. Heparin-regulated release of growth factors in vitro and angiogenic response in vivo to implanted hyaluronan hydrogels containing VEGF and bFGF. Biomaterials 27, 5242-5251 (2006).
33. Thatiparti, T. R., Shoffstall, A. J. & von Recum, H. A. Cyclodextrin-based device coatings for affinity-based release of antibiotics. Biomaterials 31, 2335-2347 (2010).
34. Conrad, H. E. Heparin-Binding Proteins (Academic, 1997).
35. Silva, E. A. & Mooney, D. J. Effects of VEGF temporal and spatial presentation on angiogenesis. Biomaterials 31, 1235-1241 (2010).
36. Freeman, I., Kedem, A. & Cohen, S. The effect of sulfation of alginate hydrogels on the specific binding and controlled release of heparin-binding proteins. Biomaterials 29, 3260-3268 (2008).
37. Stockwell, A. F., Davis, S. S. & Walker, S. E. In vitro evaluation of alginate gel systems as sustained release drug delivery systems. J. Control. Release 3, 167-175 (1986).
38. Vlatakis, G., Andersson, L. I., Muller, R. & Mosbach, K. Drug assay using antibody mimics made by molecular imprinting. Nature 361, 645-647 (1993).
39. Hiratani, H., Mizutani, Y. & Alvarez-Lorenzo, C. Controlling drug release from imprinted hydrogels by modifying the characteristics of the imprinted cavities. Macromol. Biosci. 5, 728-733 (2005).
40. Alvarez-Lorenzo, C. & Concheiro, A. Molecularly imprinted polymers for drug delivery. J. Chromatogr. B 804, 231-245 (2004).
41. Rachkov, A. & Minoura, N. Towards molecularly imprinted polymers selective to peptides and proteins. The epitope approach. Biochim. Biophys. Acta 1544, 255-266 (2001).
42. Richardson, T. P., Peters, M. C., Ennett, A. B. & Mooney, D. J. Polymeric system for dual growth factor delivery. Nature Biotechnol. 19, 1029-1034 (2001).
43. Ishihara, M. et al. Controlled release of fibroblast growth factors and heparin from photocrosslinked chitosan hydrogels and subsequent effect on in vivo vascularization. J. Biomed. Mater. Res. A 64, 551-559 (2003).
44. Wood, K. C., Chuang, H. F., Batten, R. D., Lynn, D. M. & Hammond, P. T. Controlling interlayer diffusion to achieve sustained, multiagent delivery from layer-by-layer thin films. Proc. Natl Acad. Sci. USA 103, 10207-10212 (2006).
45. Hammond, P. T. Form and function in multilayer assembly: New applications at the nanoscale. Adv. Mater. 16, 1271-1293 (2004).
46. Macdonald, M. L. et al. Tissue integration of growth factor-eluting layer-by-layer polyelectrolyte multilayer coated implants. Biomaterials 32, 1446-1453 (2011).
47. Leong, K. W., Brott, B. C. & Langer, R. Bioerodible polyanhydrides as drugcarrier matrices. I: Characterization, degradation, and release characteristics. J. Biomed. Mater. Res. 19, 941-955 (1985).
48. Wood, K. C. et al. Electroactive controlled release thin films. Proc. Natl Acad. Sci. USA 105, 2280-2285 (2008).
49. Kost, J., Leong, K. & Langer, R. Ultrasound-enhanced polymer degradation and release of incorporated substances. Proc. Natl Acad. Sci. USA 86, 7663-7666 (1989).
50. Liu, T-Y., Hu, S-H., Liu, T-Y., Liu, D-M. & Chen, S-Y. Magnetic-sensitive behavior of intelligent ferrogels for controlled release of drug. Langmuir 22, 5974-5978 (2006).
51. Santini, J. T., Cima, M. J. & Langer, R. A controlled-release microchip. Nature 397, 335-338 (1999).
52. Pitt, W. G., Husseini, G. A. & Staples, B. J. Ultrasonic drug delivery: A general review. Expert Opin. Drug Deliv. 1, 37-56 (2004).
53. Zhao, X. et al. Active scaffolds for on-demand drug and cell delivery. Proc. Natl Acad. Sci. USA 108, 67-72 (2011).
54. Murdan, S. Electro-responsive drug delivery from hydrogels. J. Control. Release 92, 1-17 (2003).
55. Sawahata, K., Hara, M., Yasunaga, H. & Osada, Y. Electrically controlled drug delivery system using polyelectrolyte gels. J. Control. Release 14, 253-262 (1990).
56. Farra, R. et al. First-in-human testing of a wirelessly controlled drug delivery microchip. Sci. Transl. Med. 4, 122ra21 (2012).
57. Lutolf, M. P. & Hubbell, J. A. Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering. Nature Biotechnol. 23, 47-55 (2005).
58. Kuhl, P. R. & Griffith-Cima, L. G. Tethered epidermal growth factor as a paradigm for growth factor-induced stimulation from the solid phase. Nature Med. 2, 1022-1027 (1996).
59. Mann, B. K., Schmedlen, R. H. & West, J. L. Tethered-TGF-β increases extracellular matrix production of vascular smooth muscle cells. Biomaterials 22, 439-444 (2001).
60. Liu, H-W., Chen, C-H., Tsai, C-L., Lin, I-H. & Hsiue, G-H. Heterobifunctional poly(ethylene glycol)-tethered bone morphogenetic protein-2-stimulated bone marrow mesenchymal stromal cell differentiation and osteogenesis. Tissue Eng. 13, 1113-1124 (2007).
61. Schense, J. C. & Hubbell, J. A. Cross-linking exogenous bifunctional peptides into fibrin gels with factor XIIIa. Bioconjug. Chem. 10, 75-81 (1999).
62. Hubbell, J. A. Bioactive biomaterials. Curr. Opin. Biotechnol. 10, 123-129 (1999).
63. Ito, Y. Covalently immobilized biosignal molecule materials for tissue engineering. Soft Matter 4, 46-56 (2008).
64. Sakiyama-Elbert, S. E., Panitch, A. & Hubbell, J. A. Development of growth factor fusion proteins for cell-triggered drug delivery. FASEB J. 15, 1300-1302 (2001).
65. Schmoekel, H. G. et al. Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices. Biotechnol. Bioeng. 89, 253-262 (2005).
66. BCC Research Advanced Drug Delivery Systems: Technologies and Global Markets (2011); http://www.bccresearch.com
67. Markets and Markets Global Biomaterial Market (2010-2015) (2011); http://www.marketsandmarkets.com
68. Centers for Disease Control and Prevention (CDC) Number of All-listed Procedures for Discharges from Short-Stay Hospitals, by Procedure Category and Sex: United States, 2010. (2011); available via http://go.nature.com/Xu3rNU
69. Moses, J. W. et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. New Engl. J. Med. 349, 1315-1323 (2003).
70. Stone, G. W. et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. New Engl. J. Med. 350, 221-231 (2004).
71. Hwang, C. W., Wu, D. & Edelman, E. R. Physiological transport forces govern drug distribution for stent-based delivery. Circulation 104, 600-605 (2001).
72. Burt, H. M. & Hunter, W. L. Drug-eluting stents: A multidisciplinary success story. Adv. Drug Deliv. Rev. 58, 350-357 (2006).
73. Stefanini, G. G. et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 378, 1940-1948 (2011).
74. Byrne, R. A. et al. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. J. Am. Coll. Cardiol. 58, 1325-1331 (2011).
75. Joner, M. et al. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 48, 193-202 (2006).
76. Dudek, D. et al. Four-year clinical follow-up of the ABSORB everolimus-eluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: the ABSORB trial. EuroIntervention 7, 1060-1061 (2012).
77. Wieneke, H. et al. Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits. Catheter Cardiovasc. Interv. 60, 399-407 (2003).
78. Kollum, M. et al. Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis. Catheter Cardiovasc. Interv. 64, 85-90 (2005).
79. Tang, C. et al. The impact of vascular endothelial growth factor-transfected human endothelial cells on endothelialization and restenosis of stainless steel stents. J. Vasc. Surg. 53, 461-471 (2011).
80. Boden, S. D., Zdeblick, T. A., Sandhu, H. S. & Heim, S. E. The use of rhBMP-2 in interbody fusion cages: Definitive evidence of osteoinduction in humans. A preliminary report. Spine 25, 376-381 (2000).
81. Govender, S. et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: A prospective, controlled, randomized study of four hundred and fifty patients. J. Bone Joint Surg. Am. 84, 2123-2134 (2002).
82. McKay, W. F., Peckham, S. M. & Badura, J. M. A comprehensive clinical review of recombinant human bone morphogenetic protein-2 (INFUSE® Bone Graft). Int. Orthop. 31, 729-734 (2007).
83. White, A. P. et al. Clinical applications of BMP-7/OP-1 in fractures, nonunions and spinal fusion. Int. Orthop. 31, 735-741 (2007).
84. Carragee, E. J., Hurwitz, E. L. & Weiner, B. K. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: Emerging safety concerns and lessons learned. Spine J. 11, 471-491 (2011).
85. Simmons, C. A., Alsberg, E., Hsiong, S., Kim, W. J. & Mooney, D. J. Dual growth factor delivery and controlled scaffold degradation enhance in vivo bone formation by transplanted bone marrow stromal cells. Bone 35, 562-569 (2004).
86. Hosseinkhani, H., Hosseinkhani, M., Khademhosseini, A. & Kobayashi, H. Bone regeneration through controlled release of bone morphogenetic protein-2 from 3-D tissue engineered nano-scaffold. J. Control. Release 117, 380-386 (2007).
87. Yamamoto, M., Takahashi, Y. & Tabata, Y. Controlled release by biodegradable hydrogels enhances the ectopic bone formation of bone morphogenetic protein. Biomaterials 24, 4375-4383 (2003).
88. Turing, A. M. The chemical basis of morphogenesis. Phil. Trans. R. Soc. Lond. B 641, 33-72 (1952).
89. Yuen, W. W., Du, N. R., Chan, C. H., Silva, E. A. & Mooney, D. J. Mimicking nature by codelivery of stimulant and inhibitor to create temporally stable and spatially restricted angiogenic zones. Proc. Natl Acad. Sci. USA 107, 17933-17938 (2010).
90. Bragdon, C. R., Jasty, M., Greene, M., Rubash, H. E. & Harris, W. H. Biologic fixation of total hip implants. Insights gained from a series of canine studies. J. Bone Joint Surg. Am. 86-A Suppl 2, 105-117 (2004).
91. Simion, M. et al. Vertical ridge augmentation using an equine block infused with recombinant human platelet-derived growth factor-BB: A histologic study in a canine model. Int. J. Periodont. Restor. Dent. 29, 245-255 (2009).
92. Simion, M., Rocchietta, I., Kim, D., Nevins, M. & Fiorellini, J. Vertical ridge augmentation by means of deproteinized bovine bone block and recombinant human platelet-derived growth factor-BB: A histologic study in a dog model. Int. J. Periodont. Restor. Dent. 26, 415-423 (2006).
93. Jaklenec, A., Stamp, A., Deweerd, E., Sherwin, A. & Langer, R. Progress in the tissue engineering and stem cell industry: "Are we there yet?" Tissue Eng. B Rev. 18, 155-166 (2012).
94. Langer, R. & Vacanti, J. Tissue engineering. Science 260, 920-926 (1993).
95. Mooney, D. J. & Vandenburgh, H. Cell delivery mechanisms for tissue repair. Cell Stem Cell 2, 205-213 (2008).
96. Hofmann, M. et al. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 111, 2198-2202 (2005).
97. Toma, C. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 105, 93-98 (2002).
98. Fisher, R. A. & Strom, S. C. Human hepatocyte transplantation: Worldwide results. Transplantation 82, 441-449 (2006).
99. Kim, B. S., Baez, C. E. & Atala, A. Biomaterials for tissue engineering. World J. Urol. 18, 2-9 (2000).
100. Malafaya, P. B., Silva, G. A. & Reis, R. L. Natural-origin polymers as carriers and scaffolds for biomolecules and cell delivery in tissue engineering applications. Adv. Drug Deliv. Rev. 59, 207-233 (2007).
101. Sittinger, M., Hutmacher, D. W. & Risbud, M. V. Current strategies for cell delivery in cartilage and bone regeneration. Curr. Opin. Biotechnol. 15, 411-418 (2004).
102. Chastain, S. R., Kundu, A. K., Dhar, S., Calvert, J. W. & Putnam, A. J. Adhesion of mesenchymal stem cells to polymer scaffolds occurs via distinct ECM ligands and controls their osteogenic differentiation. J. Biomed. Mater. Res. 78, 73-85 (2006).
103. Cooper, M. L. et al. In vivo optimization of a living dermal substitute employing cultured human fibroblasts on a biodegradable polyglycolic acid or polyglactin mesh. Biomaterials 12, 243-248 (1991).
104. Mooney, D. J. et al. Biodegradable sponges for hepatocyte transplantation. J. Biomed. Mater. Res. 29, 959-965 (1995).
105. Cao, Y., Vacanti, J. P., Paige, K. T., Upton, J. & Vacanti, C. A. Transplantation of chondrocytes utilizing a polymer-cell construct to produce tissueengineered cartilage in the shape of a human ear. Plast. Reconstr. Surg. 100, 297-302 (1997).
106. Barrera, D. A., Zylstra, E., Lansbury, P. T. & Langer, R. Synthesis and RGD peptide modification of a new biodegradable copolymer: poly(lactic acid-co-lysine). J. Am. Chem. Soc. 115, 11010-11011 (1993).
107. Hersel, U., Dahmen, C. & Kessler, H. RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. Biomaterials 24, 31-31 (2003).
108. Smetana, K. Cell biology of hydrogels. Biomaterials 14, 1046-1050 (1993).
109. Rowley, J. A., Madlambayan, G. & Mooney, D. J. Alginate hydrogels as synthetic extracellular matrix materials. Biomaterials 20, 45-53 (1999).
110. Alsberg, E. Engineering growing tissues. Proc. Natl Acad. Sci. USA 99, 12025-12030 (2002).
111. Alsberg, E., Anderson, K. W., Albeiruti, A., Franceschi, R. T. & Mooney, D. J. Cell-interactive alginate hydrogels for bone tissue engineering. J. Dent. Res. 80, 2025-2029 (2001).
112. Harris, L., Kim, B. & Mooney, D. Open pore biodegradable matrices formed with gas foaming. J. Biomed. Mater. Res. 42, 396-402 (1998).
113. Mooney, D. J., Baldwin, D. F., Suh, N. P., Vacanti, J. P. & Langer, R. Novel approach to fabricate porous sponges of poly(d,l-lactic-co-glycolic acid) without the use of organic solvents. Biomaterials 17, 1417-1422 (1996).
114. O'Brien, F. J., Harley, B. A., Yannas, I. V. & Gibson, L. J. The effect of pore size on cell adhesion in collagen-GAG scaffolds. Biomaterials 26, 433-441 (2005).
115. Mikos, A. G., Sarakinos, G., Leite, S. M., Vacanti, J. P. & Langer, R. Laminated three-dimensional biodegradable foams for use in tissue engineering. Biomaterials 14, 323-330 (1993).
116. Mikos, A. G. et al. Preparation of poly(glycolic acid) bonded fiber structures for cell attachment and transplantation. J. Biomed. Mater. Res. 27, 183-189 (1993).
117. Giordano, R. A. et al. Mechanical properties of dense polylactic acid structures fabricated by three dimensional printing. J. Biomater. Sci. Polym. Edn 8, 63-75 (1997).
118. Mironov, V., Boland, T., Trusk, T., Forgacs, G. & Markwald, R. R. Organ printing: Computer-aided jet-based 3D tissue engineering. Trends Biotechnol. 21, 157-161 (2003).
119. Compton, C. C., Butler, C. E., Yannas, I. V., Warland, G. & Orgill, D. P. Organized skin structure is regenerated in vivo from collagen-GAG Matrices seeded with autologous keratinocytes. J. Investig. Dermatol. 110, 908-916 (1998).
120. Atala, A., Oberpenning, F., Meng, J. & Yoo, J. J. De novo reconstitution of a functional mammalian urinary bladder by tissue engineering. Nature Biotechnol. 17, 149-155 (1999).
121. Nicodemus, G. D. & Bryant, S. J. Cell encapsulation in biodegradable hydrogels for tissue engineering applications. Tissue Eng. B Rev. 14, 149-165 (2008).
122. Boontheekul, T., Kong, H. & Mooney, D. Controlling alginate gel degradation utilizing partial oxidation and bimodal molecular weight distribution. Biomaterials 26, 2455-2465 (2005).
123. O'Sullivan, E. S., Vegas, A., Anderson, D. G. & Weir, G. C. Islets transplanted in immunoisolation devices: a review of the progress and the challenges that remain. Endocr. Rev. 32, 827-844 (2011).
124. Sun, Y., Ma, X., Zhou, D., Vacek, I. & Sun, A. M. Normalization of diabetes in spontaneously diabetic cynomologus monkeys by xenografts of microencapsulated porcine islets without immunosuppression. J. Clin. Investig. 98, 1417-1422 (1996).
125. Chang, T. M. S. Artificial liver support based on artificial cells with emphasis on encapsulated hepatocytes. Artif. Organs 16, 71-74 (2008).
126. Lutolf, M. P., Gilbert, P. M. & Blau, H. M. Designing materials to direct stem-cell fate. Nature 462, 433-441 (2009).
127. Brown, K. V. et al. Improving bone formation in a rat femur segmental defect by controlling bone morphogenetic protein-2 release. Tissue Eng. A 17, 1735-1746 (2011).
128. Kolambkar, Y. M. et al. An alginate-based hybrid system for growth factor delivery in the functional repair of large bone defects. Biomaterials 32, 65-74 (2011).
129. Lucas, P. A. et al. Ectopic induction of cartilage and bone by watersoluble proteins from bovine bone using a polyanhydride delivery vehicle. J. Biomed. Mater. Res. 24, 901-911 (1990).
130. Hedberg, E. L. et al. Effect of varied release kinetics of the osteogenic thrombin peptide TP508 from biodegradable, polymeric scaffolds on bone formation in vivo. J. Biomed. Mater. Res. 72A, 343-353 (2005).
131. Loeser, R. F. Aging and osteoarthritis: the role of chondrocyte senescence and aging changes in the cartilage matrix. Osteoarthr. Cartilage 17, 971-979 (2009).
132. Steadman, J. R. et al. Outcomes of microfracture for traumatic chondral defects of the knee: Average 11-year follow-up. Arthroscopy 19, 477-484 (2003).
133. Breinan, H. A., Martin, S. D., Hsu, H.-P. & Spector, M. Healing of canine articular cartilage defects treated with microfracture, a type-II collagen matrix, or cultured autologous chondrocytes. J. Orthop. Res. 18, 781-789 (2000).
134. Noth, U., Steinert, A. F. & Tuan, R. S. Technology insight: adult mesenchymal stem cells for osteoarthritis therapy. Nature Clin. Pract. Rheumatol. 4, 371-380 (2008).
135. Gille, J. et al. Mid-term results of autologous matrix-induced chondrogenesis for treatment of focal cartilage defects in the knee. Knee Surg. Sports Traumatol. Arthrosc. 18, 1456-1464 (2010).
136. Lee, C. H. et al. Regeneration of the articular surface of the rabbit synovial joint by cell homing: A proof of concept study. Lancet 376, 440-448 (2010).
137. Huang, Q., Goh, J. C. H., Hutmacher, D. W. & Lee, E. H. In vivo mesenchymal cell recruitment by a scaffold loaded with transforming growth factor β1 and the potential for in situ chondrogenesis. Tissue Eng. 8, 469-482 (2002).
138. Driver, V. R., Fabbi, M., Lavery, L. A. & Gibbons, G. The costs of diabetic foot: the economic case for the limb salvage team. J. Am. Podiat. Med. Assoc. 100, 335-341 (2010).
139. Lynch, S. E., Nixon, J. C., Colvin, R. B. & Antoniades, H. N. Role of plateletderived growth factor in wound healing: Synergistic effects with other growth factors. Proc. Natl Acad. Sci. USA 84, 7696-7700 (1987).
140. Metcalfe, A. D. & Ferguson, M. W. J. Tissue engineering of replacement skin: the crossroads of biomaterials, wound healing, embryonic development, stem cells and regeneration. J. R. Soc. Interface 4, 413-437 (2007).
141. Yannas, I. V. & Burke, J. F. Design of an artificial skin. I. Basic design principles. J. Biomed. Mater. Res. 14, 65-81 (1980).
142. Pandit, A., Ashar, R. & Feldman, D. The effect of TGF-beta delivered through a collagen scaffold on wound healing. J. Investig. Surg. 12, 89-100 (1999).
143. Kawai, K., Suzuki, S., Tabata, Y., Ikada, Y. & Nishimura, Y. Accelerated tissue regeneration through incorporation of basic fibroblast growth factor-impregnated gelatin microspheres into artificial dermis. Biomaterials 21, 489-499 (2000).
144. Gu, D. Adenovirus encoding human platelet-derived growth factor-B delivered in collagen exhibits safety, biodistribution, and immunogenicity profiles favorable for clinical use. Mol. Ther. 9, 699-711 (2004).
145. Huang, Y-C., Kaigler, D., Rice, K. G., Krebsbach, P. H. & Mooney, D. J. Combined angiogenic and osteogenic factor delivery enhances bone marrow stromal cell-driven bone regeneration. J. Bone Miner. Res. 20, 848-857 (2004).
146. Kofron, M. D. & Laurencin, C. T. Bone tissue engineering by gene delivery. Adv. Drug Deliv. Rev. 58, 555-576 (2006).
147. Peterson, B. et al. Healing of critically sized femoral defects, using genetically modified mesenchymal stem cells from human adipose tissue. Tissue Eng. 11, 120-129 (2005).
148. Sugiyama, O. et al. Lentivirus-mediated gene transfer induces long-term transgene expression of BMP-2 in vitro and new bone formation in vivo. Mol. Ther. 11, 390-398 (2005).
149. Geiger, F. et al. VEGF producing bone marrow stromal cells (BMSC) enhance vascularization and resorption of a natural coral bone substitute. Bone 41, 516-522 (2007).
150. Jabbarzadeh, E. et al. Induction of angiogenesis in tissue-engineered scaffolds designed for bone repair: A combined gene therapy-cell transplantation approach. Proc. Natl Acad. Sci. USA 105, 11099-11104 (2008).
151. Peng, H. et al. Synergistic enhancement of bone formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J. Clin. Investig. 110, 751-759 (2002).
152. Blumenthal, B. et al. Polyurethane scaffolds seeded with genetically engineered skeletal myoblasts: A promising tool to regenerate myocardial function. Artif. Organs 34, E46-E54 (2010).
153. Egana, J. T. et al. Use of human mesenchymal cells to improve vascularization in a mouse model for scaffold-based dermal regeneration. Tissue Eng. A 15, 1191-1200 (2008).
154. Park, H., Temenoff, J. S., Tabata, Y., Caplan, A. I. & Mikos, A. G. Injectable biodegradable hydrogel composites for rabbit marrow mesenchymal stem cell and growth factor delivery for cartilage tissue engineering. Biomaterials 28, 3217-3227 (2007).
155. Koffler, J. et al. Improved vascular organization enhances functional integration of engineered skeletal muscle grafts. Proc. Natl Acad. Sci. USA 108, 14789-14794 (2011).
156. Kneser, U. et al. Long-term differentiated function of heterotopically transplanted hepatocytes on three-dimensional polymer matrices. J. Biomed. Mater. Res. 47, 494-503 (1999).
157. Bruns, H. et al. Injectable liver: A novel approach using fibrin gel as a matrix for culture and intrahepatic transplantation of hepatocytes. Tissue Eng. 11, 1718-1726 (2005).
158. Vandenburgh, H. et al. Tissue-engineered skeletal muscle organoids for reversible gene therapy. Hum. Gene Ther. 7, 2195-2200 (1996).
159. Borselli, C., Cezar, C. A., Shvartsman, D., Vandenburgh, H. H. & Mooney, D. J. The role of multifunctional delivery scaffold in the ability of cultured myoblasts to promote muscle regeneration. Biomaterials 32, 8905-8914 (2011).
160. Silva, E. A., Kim, E-S., Kong, H. J. & Mooney, D. J. Material-based deployment enhances efficacy of endothelial progenitor cells. Proc. Natl Acad. Sci. USA 105, 14347-14352 (2008).
161. Ali, O. A., Huebsch, N., Cao, L., Dranoff, G. & Mooney, D. J. Infection-mimicking materials to program dendritic cells in situ. Nature Mater. 8, 151-158 (2009).
162. Ali, O. A., Emerich, D., Dranoff, G. & Mooney, D. J. In situ regulation of DC subsets and T cells mediates tumor regression in mice. Sci. Transl. Med. 1, 8ra19 (2009).
163. Kong, H., Lee, K. & Mooney, D. Decoupling the dependence of rheological/ mechanical properties of hydrogels from solids concentration. Polymer 43, 6239-6246 (2002).
164. Chenite, A. et al. Novel injectable neutral solutions of chitosan form biodegradable gels in situ. Biomaterials 21, 2155-2161 (2000).
165. Liu, X., Jin, X. & Ma, P. X. Nanofibrous hollow microspheres self-assembled from star-shaped polymers as injectable cell carriers for knee repair. Nature Mater. 10, 398-406 (2011).